Huntington's Disease (HD) Model
Creative Bioarray provides tailored contract research services that harness the power of Huntington's disease (HD) mice to evaluate the efficacy of novel genetic therapies, biologics, and small molecules aimed at targeting HD, or to study the mechanism of HD. Our cutting-edge approach enables us to deliver precise and comprehensive results that can help accelerate the development of new treatments for HD, ultimately improving the lives of patients.
HD is a neurodegenerative disorder that invariably leads to fatal outcomes, caused by a mutation in the interesting transcript 15 (IT15) gene. This mutation involves an expanded trinucleotide repeat (CAG) within exon 1 of the huntingtin (HTT) gene, resulting in the production of a mutant HTT protein that contains an abnormally long polyglutamine repeat. The disease is characterized by progressive deterioration of cognitive and motor functions, along with the selective loss of GABAergic medium spiny striatal neurons and glutamatergic cortical neurons projecting to the striatum.
Currently, HD remains an incurable and irreversible neurological disorder, necessitating urgent research for effective therapeutic interventions. Utilizing animal models for drug development against HD offers immense potential in this field. At Creative Bioarray, we have established an extensive range of transgenic models to provide a robust platform for screening potential therapeutic candidates.
Our Huntington's Disease (HD) Model
- Available Animal
Transgenic mouse - Group Setting
- Control group
- Model group
- Three dose groups of test compound
- Endpoints
- Behavioral tests: Rotarod test, Grip strength test, etc.
- Body weight
- Survival rate
- Brain weight
- Other customized endpoints: available upon request
……
Quotation and Ordering
Creative Bioarray is dedicated to providing world-class services for our clients to develop effective and efficient therapeutic interventions. We take pride in our preclinical service section, which is one of the most experienced in the world when it comes to screening and testing experimental therapeutics of CNS disorders. If you are interested in our service, please feel free to contact us or submit an inquiry to us directly.
